Michael O'Neill

This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignees: Abrexa Pharmaceuticals, Inc., Research Development Foundation. Active years: 2019-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael O'Neill. Retrieved from https://idiyas.com/inventor/michael-o-neill-pc1ml2pa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

2 out of 5

Abrexa Pharmaceuticals, Inc.

patents

2 out of 299

Research Development Foundation

patents

Years Active: 2019-2023

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11584711 - 2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene] method of making the same (2023-02-21),

2. 10968167 - 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene] hydrazide polymorphs and method of making the same (2021-04-06),

3. 10934267 - Alpha-tea salt forms: compositions and uses for treating disease (2021-03-02),

4. 10370350 - Alpha-TEA salt forms: compositions and uses for treating disease (2019-08-06),

Title: Michael O'Neill: Innovator in Neurotrophic Agents

Introduction

Michael O'Neill is a notable inventor based in Concord, OH (US). He has made significant contributions to the field of neurotrophic agents, holding a total of 4 patents. His work focuses on the development of innovative methods and compounds that have potential applications in various therapeutic areas.

Latest Patents

O'Neill's latest patents include groundbreaking work on 2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene] and its crystalline polymorph forms. He has developed methods for producing these polymorphic forms of the neurotrophic agent J147, which is known for its potential neuroprotective properties. His patents detail the processes for creating these compounds, showcasing his expertise in chemical synthesis and formulation.

Career Highlights

Throughout his career, Michael O'Neill has worked with several prominent organizations. He has been associated with the Research Development Foundation and Abrexa Pharmaceuticals, Inc., where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding and application of neurotrophic agents in medical science.

Collaborations

O'Neill has collaborated with notable colleagues in his field, including Barbara Kidon and Hongqiao Wu. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Michael O'Neill's contributions to the field of neurotrophic agents through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of therapeutic solutions in neuroscience.

Profile summary based on public USPTO records.